radiopharmaceutical

Garching/Munich, Germany and Princeton, New Jersey, August 10, 2026 ITM Isotope Technologies Munich SE (ITM) announced that the U.S....

SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...

Melbourne, Australia & Indianapolis, Indiana, USA | July 22, 2026 Telix Pharmaceuticals announced the peer-reviewed publication of results from...

BOTHELL, Wash., July 20, 2026 Immunome, Inc. (Nasdaq: IMNM) announced that the first patient has been dosed in the...

MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...

FLORHAM PARK, N.J., July 15, 2026 Cellectar Biosciences announced the publication of results from its Phase 1 dose-escalation study...

SYDNEY, Australia, March 31, 2026 Clarity Pharmaceuticals has announced the publication of Phase II Co-PSMA clinical trial results in...